← Back to headlines
Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial
Vertex Pharmaceuticals stock is rising following the release of positive interim data from its Phase 3 clinical trial for IgAN.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
